On September 8, 2026 BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T cell therapies to treat tumors in the central nervous system, reported the initiation of a pivotal Phase 2 clinical trial to evaluate BCB-276, its investigational B7-H3-targeted autologous CAR T cell therapy, for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and aggressive pediatric brainstem tumor with limited treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ILLUMINATE Phase 2 clinical trial (NCT07680439) is an open label, single-arm study to evaluate the efficacy and confirm the safety of BCB-276 in children and young adults with newly diagnosed DIPG following initial standard-of-care focal radiation therapy. The trial is designed as a single arm, pivotal Phase 2 registrational trial to accelerate the path to submit a biologics license application (BLA) for BCB-276 for the treatment of DIPG, based on alignment with the U.S. Food and Drug Administration (FDA). BCB-276 has also received Fast Track designation, further supporting an expedited development and regulatory review pathway. The multi-center study will be conducted at leading pediatric neuro-oncology centers throughout the United States. Site activation is complete or underway across all six selected and qualified study sites.

"Bringing this pivotal Phase 2 study forward for children battling DIPG has been our steadfast purpose at BrainChild Bio and represents the hard work of our team and the opportunity to advance our mission to combat pediatric brain cancer," stated Michael Jensen, MD, Founder and Chief Scientific Officer of BrainChild Bio. "We aspire to bring breakthrough medicines to these children, providing hope for cures that are safe and preserve quality of life."

As an autologous CAR T cell therapy, BCB-276 is manufactured from the participant’s own immune cells, and the treatment is administered by locoregional delivery directly into the cerebrospinal fluid using an indwelling reservoir-catheter device. Patients in the study receive BCB-276 approximately every 2 weeks for a planned course of up to a total of 15 doses over approximately 7-8 months. The primary endpoint of the study is overall survival, and secondary endpoints include safety and tolerability, progression free survival, and radiographic response.

"Children and families facing a diagnosis of DIPG urgently need new treatment options. While we recognize the significant challenges in developing new therapies for DIPG, we are hopeful that our ILLUMINATE study will bring us closer to transforming the treatment landscape and delivering a meaningful therapeutic advance for these children," said Cori Abikoff, MD, Vice President of Clinical Development. "The pivotal Phase 2 ILLUMINATE study represents an important step in evaluating the potential of BCB-276 for children with newly diagnosed DIPG. We are partnering closely with leading pediatric neuro-oncology investigators and study sites to conduct this trial with the urgency and scientific rigor that this aggressive brain cancer demands."

BrainChild Bio’s autologous B7-H3 CAR T cell therapy is based on a CAR T cell therapy that Dr. Michael Jensen and his team developed at Seattle Children’s for the treatment of DIPG, which was exclusively licensed to BrainChild Bio. In an FDA authorized clinical study, called the BrainChild-03 Phase 1 trial (NCT04185038), the CAR T cell therapy exhibited a manageable safety profile in the context of outpatient administration and provided preliminary evidence of encouraging overall survival outcomes. The results of this trial were published in Nature Medicine.

About Diffuse Intrinsic Pontine Glioma (DIPG) and Application of CAR T cell Therapies

Diffuse intrinsic pontine glioma (DIPG) is a primary high-grade brain tumor that arises in the pons and is uniformly fatal. DIPG affects approximately 300 children per year in the U.S. with the majority of diagnoses made in children between 5 and 10 years of age. Current standard-of-care treatment remains limited to palliative focal radiation therapy which results in a median overall survival of only about 11 months from diagnosis.1

BrainChild Bio’s autologous CAR T cell therapy offers the potential to overcome barriers to effective therapies for DIPG, including the precarious location of the tumor in the brainstem, the infiltrative growth of the tumor throughout normal brainstem functional anatomy, and the blood brain barrier that remains relatively intact during tumor progression. BrainChild Bio’s CAR T cell therapies are engineered to be administered by locoregional delivery directly into the cerebrospinal fluid, permitting infused CAR T cells to directly access the tumor bed using an in-dwelling reservoir-catheter. This allows for extensive exposure of the pons to cerebrospinal fluid flow from the ventricular system, repetitive infusions of CAR T cells for more durable and sustained efficacy, and local therapeutic administration to minimize on-target, off-tumor toxicities.

(Press release, BrainChild Bio, SEP 8, 2026, View Source [SID1234670656])

On September 8, 2026 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY. Management will participate in a fireside chat on Tuesday, September 15, 2026, at 1:05 pm Eastern Time and will also participate in one-on-one investor meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

(Press release, Erasca, SEP 8, 2026, View Source [SID1234670655])

On September 8, 2026 Cloverleaf Bio ("Cloverleaf"), an RNA therapeutics company developing a novel class of engineered transfer RNA (tRNA) based payloads for cancer, reported the closing of a $33 million seed financing round. The upsized and oversubscribed round was led by 4BIO Capital and includes meaningful participation from strategic investors AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, alongside Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The simultaneous participation of three major pharmaceutical venture arms at pre-clinical stage reflects strong industry interest in both the scientific platform and the founding team. The proceeds of the fundraise will be used to advance Cloverleaf’s two lead programs: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing and an antibody-tRNA conjugate (ATC) asset targeting colorectal cancer through preclinical development.

Cloverleaf’s platform is built around selective and durable inhibition of multiple RNA-modifying enzymes, a class of proteins that cancer cells become abnormally dependent on as they proliferate.

Austin Draycott, PhD, CEO and Co-Founder of Cloverleaf Bio, said "We are excited to secure this financing to advance a new generation of cancer therapeutics. We’re grateful to 4BIO Capital for leading this round, and to attract major strategic investors, including AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund at this stage reflects the level of scientific interest in this approach. We look forward to delivering the data that will test that conviction. We would also like to acknowledge the early support Cloverleaf received from the National Cancer Institute Small Business Innovation Research / Small Business Technology Transfer program. Federally funded research was foundational to getting this platform off the ground, and we’re proud to build on that public investment as we move toward the clinic."

Dima Kuzmin, Co-founder and Managing Partner at lead investor 4BIO Capital said: "Cloverleaf reflects the core thesis of 4BIO: backing transformative frontier science that has the potential to become an entirely new class of cancer therapeutics with applicability to every major cancer of unmet need. The team at Cloverleaf have built a highly promising platform from a first-principles insight into a mechanism that the field has largely taken for granted for sixty years. The preclinical data on potency and selectivity is compelling, and the strategic interest from three major pharma venture arms at seed reflects how seriously the broader industry is taking this approach. We are proud to lead this round and look forward to supporting the team as they advance toward the clinic."

Christina Vorvis, Ph.D., Director at AbbVie Ventures, said: "Cloverleaf’s platform reflects the kind of bold and novel scientific approaches we seek to advance. Our support of Cloverleaf, from its beginnings as a Yale spinout through its current efforts to develop next-generation RNA therapeutics, reflects how AbbVie Ventures works with emerging companies. Beyond investing capital, we engage as dedicated collaborators early on, bringing scientific and operational expertise to help turn promising science into potential new therapies."

Matthias Samwer, Director, at Boehringer Ingelheim Venture Fund, said: "Cloverleaf combines deep expertise in RNA biology with a highly innovative approach to tackling cancer. We believe its engineered tRNA platform has the potential to create an important new class of cancer medicines, and we are excited to support the company as it advances toward the clinic."

Differentiated Preclinical Profile

In preclinical studies, Cloverleaf’s lead compound, CLB-001, demonstrated significantly greater potency and selectivity for cancerous cells over healthy cells. The compound retains activity in cancer cell lines resistant to both frontline chemotherapy and current-generation ADC payloads, a meaningful finding given that treatment resistance is a major clinical challenge in colorectal cancer. CLB-001 also outperformed frontline standard of care in both hepatocellular carcinoma and lung adenocarcinoma models at substantially lower doses. Tolerability studies in animals showed no increases in markers of liver damage and no signs of systemic toxicity across the dose range tested.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Project No 1R44CA295426

(Press release, Cloverleaf Bio, SEP 8, 2026, View Source [SID1234670654])

On September 8, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, reported a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate ("ADC"), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect and Teverelix Programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CD228V now represents the principal strategic priority for Medicus, with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated clinical and translational strategy. Based on the existing biological, translational and clinical foundation, melanoma represents a compelling initial development opportunity, particularly in patients with relapsed or refractory disease.

The addition of CD228V represents a paradigm shift in Medicus’ clinical development portfolio and establishes precision oncology as a central component of the Company’s strategy.

CD228V is a second-generation ADC targeting melanotransferrin/CD228 in solid tumors. The program is supported by an active U.S. Investigational New Drug (IND), a first-in-human Phase 1 clinical study (NCT06799533), and substantial prior scientific, translational, and clinical development.

The Company believes successful demonstration of clinical proof-of-concept in melanoma, supported by an integrated translational and biomarker strategy, could provide an important foundation for subsequent development in other CD228-expressing solid tumors.

At the same time, Medicus is sharpening the development strategies for its two other therapeutic programs.

For SkinJect, the Company believes the strongest risk-adjusted opportunity lies in Gorlin syndrome rather than broad sporadic/nodular Basal Cell Carcinoma (BCC) lesions. FDA has authorized initiation of SKNJCT-005, the Company’s NDA-enabling registrational Phase 2b study in patients with Gorlin syndrome presenting with multiple BCCs. Gorlin syndrome is a rare autosomal dominant disease in which patients can develop numerous BCC lesions throughout their lifetime, frequently requiring repeated surgical or other lesion-directed procedures.

The Company believes concentrating SkinJect development on Gorlin syndrome could provide several potential strategic advantages beyond the more broadly competitive sporadic BCC market, which could include approvals for Orphan Drug Designation ("ODD") and Rare Pediatric Disease ("RPD") designation by the FDA as well as favorable rare-disease-anchored net pricing.

For Teverelix, Medicus intends to prioritize the optimized approximately 126-patient Phase 2 acute urinary retention ("AUR") program and PRECISION-E2, the Phase 2a study in women with symptomatic endometriosis, while continuing to advance the scientific and strategic positioning of Teverelix in advanced prostate cancer ("APC") through potential partnerships.

The Company believes this focused portfolio strategy provides multiple opportunities for meaningful clinical and shareholder value creation while enabling the Company to concentrate capital on programs with the most compelling near-term risk-adjusted potential.

(Press release, Medicus Pharma, SEP 8, 2026, View Source [SID1234670653])

On September 8, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BriaCell’s Phase 3 study now has more than 80 active clinical sites across 15 states, including Penn Medicine’s Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.

"We are pleased to welcome MSK as a clinical site in BriaCell’s Phase 3 study," stated Dr. William V. Williams, BriaCell’s President & CEO. "MSK is one of the world’s leading cancer centers, and its participation expands patient access to the Bria-IMT regimen as we continue advancing a potential new therapeutic approach for heavily pretreated patients."

"We are pleased that MSK is now enrolling patients in BriaCell’s pivotal Phase 3 study evaluating Bria-IMT for advanced breast cancer in patients with limited therapeutic options. We look forward to collaborating with BriaCell," commented Phaedon Zavras, MD, the MSK Breast Medical Oncologist and Assistant Attending Physician who is serving as principal investigator for the MSK study site.

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT in combination with an immune check point inhibitor (CPI), compared with physician’s choice of treatment in advanced metastatic breast cancer (the Bria-ABC study).

The study’s primary endpoint is overall survival (OS). An interim analysis is planned after 144 deaths have occurred, comparing OS in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice. BriaCell recently received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase 3 Study in metastatic breast cancer. At ASCO (Free ASCO Whitepaper) 2026, BriaCell also announced positive Phase 2 survival data in a similar metastatic breast cancer patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.

For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT please visit ClinicalTrials.gov NCT06072612.

Memorial Sloan Kettering Cancer Center (MSK) has institutional financial interests related to BriaCell.

(Press release, BriaCell Therapeutics, SEP 8, 2026, View Source [SID1234670652])